Share Twitter LinkedIn Facebook Email Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3 inhibition landscape in acute myeloid leukemia (AML).
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
Inequities in AML Outcomes: Comprehensive Discussion by Pramilla Krishnamurthy Acute Myelogenous Leukemia 2 Mins Read